Zde se nacházíte:
Informace o publikaci
Subgroup-specific structural variation across 1,000 medulloblastoma genomes
Autoři | |
---|---|
Rok publikování | 2012 |
Druh | Článek v odborném periodiku |
Časopis / Zdroj | Nature |
Fakulta / Pracoviště MU | |
Citace | |
Doi | http://dx.doi.org/10.1038/nature11327 |
Obor | Onkologie a hematologie |
Klíčová slova | HEDGEHOG PATHWAY INHIBITOR; COPY-NUMBER ALTERATION; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; HUMAN CANCERS; BETA FAMILY; SYNPHILIN-1; PROTEIN; MYC; CHILDHOOD |
Přiložené soubory | |
Popis | Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson's disease, which is exquisitely restricted to Group 4 alpha. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-beta signalling in Group 3, and NF-kappa B signalling in Group 4, suggest future avenues for rational, targeted therapy. |